Physician profile
Deryll U Ambrocio
NPI 1730301219
$21,071.95
in general payments reported to CMS, 2019-2025
23 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,407 · 2020: $732 · 2021: $1,099 · 2022: $3,224 · 2023: $1,558 · 2024: $2,225 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,610.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,266.74 | 2019-2025 | |
| Horizon Therapeutics Plc | $3,848.43 | 2019-2023 | Krystexxa |
| Amgen INC. | $3,406.01 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,778.40 | 2022-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,048.66 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $556.45 | 2019-2025 | |
| Insmed, INC. | $544.02 | 2019-2022 | |
| Lilly USA, LLC | $466.25 | 2019-2025 | Taltz, Olumiant |
| Aurinia Pharma U.S., INC. | $353.45 | 2021-2024 | Lupkynis |
| Sobi, INC | $152.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $87.29 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $82.51 | 2019-2024 | Orencia |
| Genentech USA, INC. | $80.16 | 2019-2025 | Gazyva |
| Radius Health, INC. | $76.16 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $64.85 | 2023-2025 | Saphnelo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $43.60 | 2023 | Strensiq |
| Sun Pharmaceutical Industries INC. | $42.74 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $34.58 | 2023-2025 | Acthar |
| Viiv Healthcare Company | $32.06 | 2023 | Apretude |
| Janssen Biotech, INC. | $31.25 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.66 | 2019 | |
| Ani Pharmaceuticals, INC. | $27.04 | 2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals, LTD. | $18.75 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deryll Ambrocio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.